Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $70 from $60 and keeps an Overweight rating on the shares following the Q3 report. The firm cites increased optimism for KT-621 for the target bump.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Reports Q3 2025 Financial Results
- Kymera Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
- Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
- Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release